RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Key Figures

Home  >  Investor Relations  >  At a Glance  >  Key Figures

Years ended December 31
$1,000 except per share data 2025 2024 2023 2022 2021
Result
Net sales 2,089,999 1,978,214 1,965,311 2,141,518 2,251,657
Operating income 465,851 97,711 409,938 531,460 630,084
Net income 424,880 83,591 341,303 423,211 512,599
Basic earnings per share (EPS) 1.96 0.38 1.50 1.86 2.25
Diluted earnings per share (EPS) 1.94 0.37 1.48 1.84 2.21
Number of shares (in thousands)
Common shares used to compute basic earnings per share1 217,219 222,619 228,146 227,577 227,983
Common shares used to compute diluted earnings per share2 218,880 224,717 230,619 230,136 232,034
Cash flow
Cash flow from operations 654,326 673,551 459,455 715,264 639,001
Capital expenditures for property, plant and equipment 201,049 167,174 149,710 129,224 189,904
Free cash flow3 453,277 506,377 309,745 586,040 449,097

As of December 31

Balance sheet
Total assets 6,281,232 5,689,622 6,115,190 6,287,735 6,146,954
Cash and cash equivalents 839,005 663,555 668,084 730,669 880,516
Total long-term liabilities, including current portion 1,990,941 1,632,135 1,816,103 2,236,153 2,380,560
Total equity 3,778,154 3,567,339 3,807,764 3,466,611 3,096,550

Please visit Financial Reports for more information.

1Weighted average number of common shares used to compute basic earnings per common share

2Weighted average number of common shares used to compute diluted earnings per common share

3Free cash flow is calculated from cash provided by operations reduced by purchases of property, plant and equipment